HAE attacks can be treated whenever and wherever they occur with RUCONEST 1

RUCONEST allows appropriately trained patients and their caregivers to treat attacks at home or on the go

Intravenous injection that can be self-administered in just 5 minutes. 1

  • 50 IU/kg for patients weighing <84 kg
  • Maximum dose of 4200 IU (2 vials) for patients weighing 84 kg

Dosing calculator

Enter weight (lb)

1 kg=2.2 lb

Recommended dose of RUCONEST for an acute attack

Dosing by body weight 1

Body weight

RUCONEST dose
for IV injection

Volume (mL) of reconstituted solution (150 IU/mL) to be administered

<84 kg

50 IU per kg

Body weight in kg divided by 3

84 kg

4200 IU (2 vials)

28 mL

IV, intravenous.

Count on plasma-free RUCONEST 1

RUCONEST is the only recombinant C1-INH indicated for the treatment of HAE attacks 1

SUPPLY

Reliable and scalable supply 2

PURITY

Contains less than
0.002% of host-related impurities 1

SAFETY

Recombinant design eliminates risk of human blood-borne pathogens 1

Pregnancy category B classification 1 ,f

fRUCONEST has not been studied in pregnant women; therefore, it should only be used during pregnancy if clearly needed. Advise patients to notify their physician if they are breastfeeding or plan to breastfeed. 1

The benefits of plasma-free

Raffi Tachdjian, MD

UCLA School of Medicine, Los Angeles, CA

RUCONEST has a well-established tolerability profile 1

Adverse reactions occurring in 2% of patients treated for an acute attack in 7 studies 1

All RUCONEST dosesg
205 total patients treated

Headache

19 patients (9%)

Nausea

5 patients (2%)

Diarrhea

5 patients (2%)

gIncluded doses up to 100 IU/kg. 1

The serious adverse reaction reported in clinical trials was anaphylaxis. 1

RUCONEST is contraindicated in patients with a history of allergy to rabbits or rabbit-derived products, and patients with a history of life-threatening immediate hypersensitivity reactions to C1 esterase inhibitor preparations, including anaphylaxis. 1

Rabbit allergy testing is not required. 1

C1-INH, C1 esterase inhibitor.

RUCONEST addresses the root cause of the attack 7,8

Powerful action upstream AND at multiple points in the inflammatory cascade 7,8

Adapted from Moldovan D, Bernstein JA, Cicardi M. Recombinant replacement therapy for hereditary angioedema due to C1 inhibitor deficiency. Immunotherapy. 2015;7(7):739-752; Kaplan AP, Joseph K, Silverberg M. Pathways for bradykinin formation and inflammatory disease. J Allergy Clin Immunol. 2002;109(2):195-209.

FXII, Factor 12; FXIIa, Factor 12a; HMW, high-molecular-weight.

Acute HAE attacks develop when there is a deficiency of the C1-INH protein, which causes the overproduction of bradykinin that leads to acute swelling. 7,8

RUCONEST raised functional C1-INH levels to normal in 94% of patients 9

Resources and Support

RUCONEST SOLUTIONS
offers individualized
support for your patients.

Learn more